ARTICLES BY MATTHEW PILLAR
-
Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific?12/19/2024
Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.
-
Inside Interius' Global Regulatory Strategy12/13/2024
Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy.
-
How Cidara Got Its Molecule Back10/30/2024
In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a deal with J&J, is now squarely back in the biotech's hands and moving forward with an aggressive phase 2b study.
-
Doubling Down On Biopharma's Growing Skills Drought3/13/2024
The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.
-
Debra Weiss, RN: Big Impact In Small, Non-Profit Bio3/8/2024
The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.
-
1 In 300 People In The U.S. Is Living With HIV. That's Not Okay With Jeff Galvin.2/12/2024
By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.
-
Accelerating Drug Development With Real World Data12/1/2023
Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.
-
Data-Driven Biopharma Leadership11/1/2023
Knowing when it’s time to raise funds, fortify a CMC initiative, hire a chief regulatory or commercial officer, or make virtually any other big money move in biopharma isn’t art, it’s science. Business progress, as in scientific progress, is a data-driven exercise.
-
Legal And IP Protection For New Biotechs10/31/2023
Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs.
-
Establishing A Research Function In Biopharma10/2/2023
When it was time to double-down on development efforts to feed its pipeline of biologics, Horizon Therapeutics turned to Big Biopharma veteran Robert Stoffel, Ph.D. to lead the effort. Stoffel joined us for an episode of the Business of Biotech podcast to share how he did it.
-
The DEI Value Proposition9/1/2023
The value of DEI initiatives sometimes get lost in their feel-good, altruistic intent. Not at Rocket Pharmaceuticals, where purposeful and specific equity and inclusion exercises pay dividends in the form of a diverse, talented, and committed workforce. President & COO Kinnari Patel, PharmD explains.
-
The Immigrant Approach To Biotech Formation8/1/2023
Flagship Pioneering General Partner Avak Kahvejian, Ph.D., says successfully ideating new biotech companies — which Flagship has done in spades — requires the curiosity, skepticism, and paranoia of a new inhabitant in foreign land. Oh, and a little bit of machine learning won’t hurt.
-
Inside M&A With Bill Symonds7/3/2023
On episode 143 of the Business of Biotech, Enzyvant CEO Bill Symonds, Pharm.D. takes us inside the rationale and execution of last year’s Enzyvant/Altavant merger.
-
Where Science Leads, Business Follows6/1/2023
Learn how science, rather than market and investor expectations, directed Francois Rieger’s oversight of the Medsenic/Bone Therapeutics merger.
-
The Hybrid Face Of Biopharma5/1/2023
What came first, the development platform or the therapeutic asset? To a growing class of biotechs, it doesn’t even matter.